
In 2023, QualityMetric (QM) became an IQVIA business. This further enabled us to provide clinical outcome assessment (COA) licensing in addition to leveraging our combined innovative technology solutions and scientific expertise. Since our full integration into IQVIA will soon be complete, it is time to retire the QM brand.
As we remain committed to our same quality licensing and services, we invite you to find the legacy QM COAs you know, in addition to the other 160+ COA offerings on IQVIA's COA Marketplace.
As pharma, biotech, medical device companies and academic researchers race to discover treatments for COVID-19, they require measurement and outcomes reporting for capturing real-world evidence.
__
On COVID-19
COVID-19 has changed the world, and as pharma, biotech, medical device companies and academic researchers race to discover treatments, they require measurement and outcomes reporting that enables them to continue their research and capture real-world evidence.
Pharma sponsors are collaborating with QualityMetric to integrate our patient-reported outcome (PRO) Solutions in COVID-19 studies to understand the significant impact of the infectious disease on functional health status burden. QualityMetric’s PROs are available in over 2,000 linguistically validated translations across electronic, interviewer script and paper mode of administration.
QualityMetric’s SF instruments are also available in daily recall as COVID-19 symptoms can rapidly progress, and custom COVID-SF-12v2 with additional questions focused on fatigue and emotional health.